FDA authorises second booster dose of two COVID-19 vaccines for older and immunocompromised individuals

FDA

29 March 2022 - Today, the U.S. FDA authorised a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals. 

The FDA previously authorised a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series. 

This action will now make a second booster dose of these vaccines available to other populations at higher risk for severe disease, hospitalisation and death. Emerging evidence suggests that a second booster dose of an mRNA COVID-19 vaccine improves protection against severe COVID-19 and is not associated with new safety concerns.

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Vaccine , COVID-19